PRX Financial Facts
Net income (loss): -0.79Income (loss) from continuing operations: -0.79
See Full Income Statement
Accrued expenses and other current liabilities: 18.81M
Goodwill: 313.34M
See Full Balance Sheet
Earnings History for Par Pharmaceutical Companies Inc. (PRX)
|
Expand Research on PRX
| Next EPS Date | 10/31/12 *Est. | EPS Growth Rate | +92.9% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | +15.3% | Revenue Growth Rate | +31.3% *Last Qtr. |
| Average % Move 1-Wk after EPS | -2.7% |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Estimize EPS/Revs | Gd. | % Since | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 8/2/12 |
Q212 | $1.62 | $1.12 | +$0.50 | $294.3M | $291.3M | N/A / N/A | N/A | +0.1% | Details | |
| 5/8/12 |
Q112 | $0.80 | $0.72 | +$0.08 | $271.5M | $230.84M | N/A / N/A | N/A | 0% | Details | |
| 2/28/12 |
Q411 | $0.78 | $0.75 | +$0.03 | $253.6M | $230.31M | N/A / N/A | N/A | +31.9% | Details | |
| 11/2/11 |
Q311 | $0.74 | $0.73 | +$0.01 | $215.4M | $309.97M | N/A / N/A | N/A | +68.5% | Details | |
| 8/3/11 |
Q211 | $0.84 | $0.77 | +$0.07 | $224.2M | $216.47M | N/A / N/A | N/A | +67.4% | Details | |
| 5/5/11 |
Q111 | $0.96 | $0.89 | +$0.07 | $233M | $227.77M | N/A / N/A | N/A | +52.1% | Details | |
| 2/24/11 |
Q410 | $0.61 | $0.67 | -$0.06 | $227M | $210.69M | N/A / N/A | N/A | +45.3% | Details | |
| 11/3/10 |
Q310 | $0.89 | $0.54 | +$0.35 | N/A | N/A | N/A / N/A | N/A | +51.1% | Details |
